open access

Vol 54, No 2 (2016)
Original paper
Submitted: 2015-09-23
Accepted: 2016-05-16
Published online: 2016-06-06
Get Citation

The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn’s disease patients in relation to mucosal healing

Piotr Eder, Liliana Lykowska-Szuber, Katarzyna Iwanik, Iwona Krela-Kazmierczak, Kamila Stawczyk-Eder, Przemyslaw Majewski, Krzysztof Linke, Elaine W. Kay, Aldona Wozniak
DOI: 10.5603/FHC.a2016.0008
·
Pubmed: 27270504
·
Folia Histochem Cytobiol 2016;54(2):75-80.

open access

Vol 54, No 2 (2016)
ORIGINAL PAPERS
Submitted: 2015-09-23
Accepted: 2016-05-16
Published online: 2016-06-06

Abstract

Introduction. Immune-mediated angiogenesis may play an important role in the pathogenesis of inflammatory lesions in Crohn’s disease (CD). The study aimed to assess the influence of anti-tumour necrosis factor (anti-TNF) therapy on the angiogenesis in relation to microscopic and endoscopic healing in CD patients.

Material and methods. Colonic tissue samples from 17 CD patients were taken during colonoscopy before and after anti-TNF therapy. Endoscopic and microscopic severities were estimated using validated scores. Immunohistochemical expression of CD31 and vascular endothelial growth factor (VEGF) were assessed in parallel.

Results. The expression of CD31 and VEGF decreased significantly after the anti-TNF therapy in parallel to endoscopic improvement; however, the microscopic activity did not change significantly. There was a correlation between the change in CD31 and VEGF expression (p = 0.01; r = 0.6), as well as endoscopic healing (p = 0.04; r = 0.4). CD31 immunoexpression correlated with the number of poly- and mononuclear cells in the infiltrates in the mucosal lamina propria before the therapy (p = 0.02; r = 0.5).

Conclusions. We suggest that modulation of vascular proliferation can be a novel option to increase the efficacy of biological therapy in CD. 

Abstract

Introduction. Immune-mediated angiogenesis may play an important role in the pathogenesis of inflammatory lesions in Crohn’s disease (CD). The study aimed to assess the influence of anti-tumour necrosis factor (anti-TNF) therapy on the angiogenesis in relation to microscopic and endoscopic healing in CD patients.

Material and methods. Colonic tissue samples from 17 CD patients were taken during colonoscopy before and after anti-TNF therapy. Endoscopic and microscopic severities were estimated using validated scores. Immunohistochemical expression of CD31 and vascular endothelial growth factor (VEGF) were assessed in parallel.

Results. The expression of CD31 and VEGF decreased significantly after the anti-TNF therapy in parallel to endoscopic improvement; however, the microscopic activity did not change significantly. There was a correlation between the change in CD31 and VEGF expression (p = 0.01; r = 0.6), as well as endoscopic healing (p = 0.04; r = 0.4). CD31 immunoexpression correlated with the number of poly- and mononuclear cells in the infiltrates in the mucosal lamina propria before the therapy (p = 0.02; r = 0.5).

Conclusions. We suggest that modulation of vascular proliferation can be a novel option to increase the efficacy of biological therapy in CD. 

Get Citation

Keywords

Crohn’s disease; anti-TNF therapy; CD31; VEGF; angiogenesis; IHC

About this article
Title

The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn’s disease patients in relation to mucosal healing

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 54, No 2 (2016)

Article type

Original paper

Pages

75-80

Published online

2016-06-06

DOI

10.5603/FHC.a2016.0008

Pubmed

27270504

Bibliographic record

Folia Histochem Cytobiol 2016;54(2):75-80.

Keywords

Crohn’s disease
anti-TNF therapy
CD31
VEGF
angiogenesis
IHC

Authors

Piotr Eder
Liliana Lykowska-Szuber
Katarzyna Iwanik
Iwona Krela-Kazmierczak
Kamila Stawczyk-Eder
Przemyslaw Majewski
Krzysztof Linke
Elaine W. Kay
Aldona Wozniak

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl